个人简介：
开展基于靶点的药物筛选评价及机理研究，以及天然产物和中药复方抗炎、抗肿瘤的机制研究，曾主持并完成2项国家自然科学基金。
授权专利：
1. 曹鹏 杨杰 钱士辉. 竹节参苷Ⅳa丁酯作为IL-6/STAT3信号通路抑制剂的应用，授权公告号:CN105582018B.
2. 杨友 曹鹏 荣晶晶 杨杰. 一种竹节参苷Ⅳa丁酯的制备方法，授权公告号：CN110684072B.
3. 曹鹏 胡春萍 杨杰 蔡雪婷 凌媛媛 华迪.一种含全蝎的中药组合物作为制备治疗类风湿关节炎骨侵蚀病药物的应用，授权公告号：CN110123868B.
4. 曹鹏 陈姣 杨杰. IDH2突变体抑制剂及其用途. 授权公告号:CN106810512B.
联系方式：
766429133@qq.com
近五年发表文章：（按照参考文献格式列举）
1. Yang J# Chen J# Chang JJ Sun XY Wei QY Cai XT Cao P*. IDH2/R140Q mutation confers cytokine‑independent proliferation of TF‑1 cells by activating constitutive STAT3/5 phosphorylation. Cell Commun Signal. 2024 Feb 12;22(1):116.
2. Wei Q# Yao K# Yang J# Zhou Q Liu P Chen J Liu H Lai Y* Cao P*. Structure-ba
3. Zhang D# Yang J# Zhao Y Shan J Wang L Yang G He S Li E. RSV Infection in Neonatal Mice Induces Pulmonary Eosinophilia Responsible for Asthmatic Reaction. Front Immunol. 2022 Feb 2;13:817113.
4. Yang J Ling YY Hua D Zhao CL Sun XY Cai XT Chen J Hu CP Cao P*. IL-6R blockade by chikusetsusaponin IVa butyl ester inhibits Th17 cell differentiation and ameliorates collagen-induced arthritis. Cell Mol Immunol. 2021 Feb 26.
5. Ling YY # Yang J# Hua D# Wang DW Zhao CL Weng L Yue DD Cai XT Meng QH Chen J Sun XY Kong WK Zhu LZ Cao P* Hu CP*. ZhijingSan inhibits osteoclastogenesis via regulating RANKL/NF-κB signaling pathway and ameliorates bone erosion in collagen-induced mouse arthritis. Front Pharmacol. 2021 May 28.
6. Hua D# Yang J# Meng QH# Ling YY Wei Q Wang ZG Wei QY Chen J Ye J Han X Kelei Su Kong WK Xu C Cao P* Hu CP*. Soufeng sanjie formula alleviates collagen-induced arthritis in mice by inhibiting Th17 cell differentiation. Chin Med. 2021 May 13;16(1):39.
7. Chen J# Yang J# Wei QY Weng L Wu F Shi Y Cheng XL Cai XT Hu CP Cao P*. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells. Cell Commun Signal. 2020 Apr;18(1):55.